Quantcast

Latest Prasugrel Stories

2010-03-15 08:30:00

PARSIPPANY, N.J. and INDIANAPOLIS, March 15 /PRNewswire-FirstCall/ -- A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix® (clopidogrel) plus aspirin or Effient® (prasugrel) plus aspirin and managed with percutaneous coronary intervention (PCI) following an acute coronary...

2010-03-15 07:30:00

SAN DIEGO, March 15 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced the presentation of a 2,000 patient meta-analysis examining patient response to antiplatelet therapy after percutaneous coronary intervention (PCI). Data from the patient-level meta-analysis show that individuals with an...

2010-02-25 09:00:00

WALTHAM, Mass., Feb. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2018 in the acute coronary syndrome drug market, the overall uptake of Eli Lilly/Daiichi Sankyo's Effient in the United States and Europe (where it is marketed as Efient) will be constrained by the widespread use of AstraZeneca's Brilinta, which is expected to launch in 2011. The Pharmacor 2010 findings from the...

2010-01-07 07:30:00

SAN DIEGO, Jan. 7 /PRNewswire/ -- Accumetrics, Inc., developer and marketer of the VerifyNow® System, the first rapid and easy-to-use diagnostic system for measuring an individual's response to multiple antiplatelet agents, announced today that the Company has received a certificate of registration to ISO 13485: 2003, the Quality Management System, a standard developed by the International Organization for Standardization for medical device manufacturers. "We are...

2010-01-05 08:00:00

PARSIPPANY, N.J. and INDIANAPOLIS, Jan. 5 /PRNewswire-FirstCall/ --Results from a health economic substudy of the TRITON-TIMI 38 clinical trial showed that among patients with acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI), including stenting, treatment with Effient(®) (prasugrel) compared with branded clopidogrel (Plavix(®)) was more cost effective, and in most cases cost saving. These results were published in...

2009-12-15 07:30:00

SAN DIEGO, Dec. 15 /PRNewswire/ -- Accumetrics, Inc., developer and marketer of the VerifyNow® System, the first rapid and easy-to-use diagnostic system for measuring an individual's response to multiple antiplatelet agents, announced that 2009 included a doubling in the number of international and U.S. distribution agreements, as well as positive medical community support, and significant capital financing that will take the company into 2011. In 2009, the company...

2009-11-24 12:00:00

SAN DIEGO, Nov. 24 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy-to-use diagnostic system for measuring an individual's response to multiple antiplatelet agents (e.g. Plavix® and aspirin), announced today that Timothy I. Still, President and CEO of Accumetrics, and Gregory J. Tibbitts, Chief Financial Officer of Accumetrics, will be presenting a corporate overview at the 21st...

2009-11-19 07:30:00

SAN DIEGO, Nov. 19 /PRNewswire/ -- Accumetrics, Inc., developer of the VerifyNow System, the first point-of-care method for measuring platelet reactivity, announces that its market-leading VerifyNow P2Y12 Test was one of multiple methods evaluated in the POPular study, which was presented during a Late Breaking Clinical Trials session at the American Heart Association's annual Scientific Sessions. The VerifyNow P2Y12 Test is used to measure the antiplatelet effect of medications, such as...

2009-11-19 01:00:00

WILMINGTON, Del., Nov. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA(TM), pending approval from the FDA. (Logo:...

2009-11-18 12:11:00

PARSIPPANY, N.J. and INDIANAPOLIS, Nov. 18 /PRNewswire-FirstCall/ -- Effient® (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardial infarction (STEMI), or severe heart attack. The two 2009 focused updates for the clinical guidelines, jointly developed by the American Heart Association...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin